MY163067A - Peg or peg block copolymers for treating colorectal cancer - Google Patents

Peg or peg block copolymers for treating colorectal cancer

Info

Publication number
MY163067A
MY163067A MYPI2013001602A MYPI2013001602A MY163067A MY 163067 A MY163067 A MY 163067A MY PI2013001602 A MYPI2013001602 A MY PI2013001602A MY PI2013001602 A MYPI2013001602 A MY PI2013001602A MY 163067 A MY163067 A MY 163067A
Authority
MY
Malaysia
Prior art keywords
peg
colorectal cancer
block copolymers
treating colorectal
treating
Prior art date
Application number
MYPI2013001602A
Other languages
English (en)
Inventor
Peter Stein
Ian Cox
Samuel Smith
Leighton Jones
Jörg Plessl
Vries Corinne De
Rachel Charlton
Original Assignee
Norgine Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norgine Bv filed Critical Norgine Bv
Publication of MY163067A publication Critical patent/MY163067A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/77Polymers containing oxygen of oxiranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
MYPI2013001602A 2010-11-04 2011-11-04 Peg or peg block copolymers for treating colorectal cancer MY163067A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1018650.0A GB201018650D0 (en) 2010-11-04 2010-11-04 Methods and compositions
US41212810P 2010-11-10 2010-11-10

Publications (1)

Publication Number Publication Date
MY163067A true MY163067A (en) 2017-08-15

Family

ID=43414365

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013001602A MY163067A (en) 2010-11-04 2011-11-04 Peg or peg block copolymers for treating colorectal cancer

Country Status (22)

Country Link
US (2) US20130216493A1 (enExample)
EP (1) EP2635289B1 (enExample)
JP (1) JP5917537B2 (enExample)
KR (1) KR20130109171A (enExample)
CN (1) CN103313719A (enExample)
AR (1) AR083770A1 (enExample)
AU (1) AU2011324996B2 (enExample)
BE (1) BE1019494A3 (enExample)
BR (1) BR112013011012A2 (enExample)
CA (1) CA2816839A1 (enExample)
EA (1) EA201300540A1 (enExample)
ES (1) ES2401269B1 (enExample)
GB (1) GB201018650D0 (enExample)
MX (1) MX349690B (enExample)
MY (1) MY163067A (enExample)
NL (1) NL2007715C2 (enExample)
NZ (1) NZ611145A (enExample)
SG (1) SG189533A1 (enExample)
TW (1) TWI606832B (enExample)
UA (1) UA107998C2 (enExample)
WO (1) WO2012059725A1 (enExample)
ZA (1) ZA201304052B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
KR20170098980A (ko) 2012-09-11 2017-08-30 노어긴 비.브이. Peg 및 아스코르베이트를 포함하는 조성물
AR093153A1 (es) * 2012-10-26 2015-05-20 Northshore Univ Healthsystem Composiciones que comprenden polietilenglicol para la terapia del carcinoma de celulas escamosas de cabeza y cuello
CN103083733A (zh) * 2013-02-19 2013-05-08 华熙福瑞达生物医药有限公司 一种医用体腔器械导入水性润滑剂
CN113507933B (zh) * 2019-03-05 2024-05-10 陶氏环球技术有限责任公司 诱导胱天蛋白酶活性
EP3934663B1 (en) * 2019-03-05 2024-06-26 Dow Global Technologies LLC Polyethyleneglycol derivatives for use in treating cancer and/or inducing caspase activity
US12251399B2 (en) 2019-03-05 2025-03-18 Dow Global Technologies Llc Inducing caspase activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2784897B1 (fr) 1998-10-27 2002-11-29 Agronomique Inst Nat Rech Utilisation d'un laxatif osmotique non fermente dans le traitement et la prevention des cancers colorectaux
AU2006244112B2 (en) * 2005-05-06 2011-02-17 Salix Pharmaceuticals, Inc. Polyethylene glycol colonic purgative composition
US8457025B2 (en) * 2009-08-28 2013-06-04 Telefonaktiebolaget L M Ericsson (Publ) Method and network node for selecting a network prefix to be advertised in a communication network

Also Published As

Publication number Publication date
US20160228467A1 (en) 2016-08-11
GB201018650D0 (en) 2010-12-22
BE1019494A3 (fr) 2012-07-03
WO2012059725A8 (en) 2013-05-30
ES2401269A1 (es) 2013-04-18
EP2635289A1 (en) 2013-09-11
MX2013004963A (es) 2013-08-27
MX349690B (es) 2017-08-09
EP2635289B1 (en) 2020-03-11
EA201300540A1 (ru) 2013-09-30
WO2012059725A1 (en) 2012-05-10
AU2011324996A1 (en) 2013-05-02
SG189533A1 (en) 2013-05-31
BR112013011012A2 (pt) 2016-08-23
AU2011324996B2 (en) 2015-10-08
JP5917537B2 (ja) 2016-05-18
CA2816839A1 (en) 2012-05-10
AR083770A1 (es) 2013-03-20
CN103313719A (zh) 2013-09-18
JP2013544809A (ja) 2013-12-19
UA107998C2 (uk) 2015-03-10
ZA201304052B (en) 2014-02-26
TW201304785A (zh) 2013-02-01
NZ611145A (en) 2015-07-31
ES2401269B1 (es) 2014-02-19
NL2007715C2 (en) 2012-10-16
TWI606832B (zh) 2017-12-01
KR20130109171A (ko) 2013-10-07
NL2007715A (en) 2012-05-07
US20130216493A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
IL261338A (en) Preparations and methods for treating broad-spectrum, undiagnosed or mixed clinical applications
MX349690B (es) Polietilenglicol (peg) o copolimeros de bloqueo de bloque de polietilenglicol (peg) para el tratamiento de cancer colorrectal.
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
BR112015007878A2 (pt) composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
WO2012076293A9 (de) Zubereitungen enthaltend polysiloxane mit stickstoffhaltigen gruppen
HK1213889A1 (zh) 殼氨醯胺酶抑制劑及使用方法
PH12015501088A1 (en) Dimeric compounds
JO3283B1 (ar) تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
BR112012011485A2 (pt) "composições e métodos para tratar náusea e vômito centralmente mediados".
EP4582090A3 (en) Composition comprising pegylated arginine deiminase
PH12012501365A1 (en) Stabilization of zinc oxide film in oral compositions
WO2012078633A3 (en) Methods of inhibiting metastasis from cancer
HK1210962A1 (en) Methods for treatment of atherosclerosis
WO2009095261A3 (en) Vaccine compositions
WO2012158672A3 (en) Compounds for use in treatment of mucositis
SG10201505676RA (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
PH12013501311A1 (en) Polymer systems
WO2012065135A3 (en) Immunomodulatory compositions, methods and systems comprising immunogenic fragments of apob100
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
WO2011100330A3 (en) Compositions and methods for preventing or treating a human parvovirus infection
PH12015500185A1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
WO2012074725A3 (en) Immunomodulatory methods and systems for treatment and/or prevention of hypertension
WO2011130692A3 (en) Androgen induced oxidative stress inhibitors